Aarti Drugs

The fall in Aarti Drugs share price came after the company reported a weak set of September quarter (Q2FY25) earnings.

Smallcap pharmaceutical company Aarti Drugs's shares climbed up to 2.95 per cent at Rs 528.85 per share on the BSE

Going ahead in FY25, the management anticipates an improvement in margins, mostly driven by an anticipated growth in export sales and backward integration.

Bayer Cropscience, Granules India and HLE Glasscoat are the other three stocks that can generate healthy returns till next Diwali, based on the existing chart patterns.

The board has approved the buyback of 665,000 equity shares at Rs 900 per share via the tender offer route

The board of directors has fixed April 1 as record date for ascertaining the shareholder who will participate in the proposed buyback.

In the past six months, the stock of Aarti Drugs has underperformed the market by falling 7 per cent as against a 29 per cent rally in the Sensex

Multiplex major PVR plans to invest Rs 150 crore to open up to 40 screens across the country in the next fiscal

Economists caution that the demand for goods and services could taper off in the months ahead

The company will intimate the "Record Date" for determining eligible shareholders entitled to receive bonus shares in due course

The company had reported 281 per cent jump in net profit in June 2020 quarter results.

These companies reported an increase in revenue and/or profit before tax for the March quarter

According to analysts at Centrum Broking, the launch of new products would improve the company's margins in the coming quarters

Market Ahead, May 15: All You Need To Know Before The Opening Bell

Today, a total of 12 companies including Cipla, Aaarti Drugs, and M&M Finance are scheduled to announce their results

Analysts believe the firm's API business will continue its growth momentum driven by capacity expansion and gain in market share in existing products

The stock dipped 6% to Rs 528 on the BSE in otherwise firm market.

The stock hit a fresh 52-week high of Rs 785, up 7% on BSE in intra-day trade, after the company's board share buyback at a price of Rs 875 per share through tender offer.

The stock surged 7% to Rs 689, also its 52-week high on NSE in early morning trade after the company said that its board will meet on January 8, to consider share buyback proposal